Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in moderate-to-severe asthma
CTR20230568Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in asthma, sponsored by Keymed Biosciences. Started Apr 2023; status: active.
02
Drugs
stapokibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20230568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230568.